UPDATE: Rexahn Pharmaceuticals (RNN) Posts Q1 Loss of 9c/Share; Updates on Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Affirms Rexahn (RNN) at 'Buy'; Things Shaping Up for Solid Second-Half 2014
May 15, 2014 8:14 AM EDTRoth Capital maintains Rexahn Pharmaceuticals (AMEX: RNN) at Buy with a target price of $3. Ahead of the bell, Rexahn reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02).
Analyst Joseph Pantginis commented, The financial results currently do not impact our investment case. Rexahn has three clinical-stage assets. Archexin is a potentially best-in-class Akt1 inhibitor. A Phase IIa study of the drug in pancreatic cancer showed that the drug is safe and well tolerated and demonstrated... More
